<DOC>
	<DOC>NCT01741701</DOC>
	<brief_summary>The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and complete two safety follow-up phone calls over a 4 month period.</brief_summary>
	<brief_title>A Pilot Study of Oxaloacetate in Subjects With Treated PD</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Able to give informed consent and follow instructions per the protocol Diagnosis of idiopathic PD within 7 years of diagnosis Taking stable doses of levodopa and would not predictably need adjustment in PD medications for 4 months Unified Parkinson's Disease Rating Scale (UPDRS) II + III at least 30 points at baseline Previously taken Oxaloacetate Participation in other drug studies or use of other investigational products within 30 days prior to baseline In the Investigator's opinion, any unstable or clinically significant condition that would impair the subjects' ability to comply with study followup Other known or suspected cause of parkinsonism</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>